Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018


January 11, 2018 As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. In 2017, Medical Technology Stock Letter had four recommendations deliver outstanding returns led by Madrigal Pharmaceuticals Inc. with a 510% move, followed by Sangamo BioSciences Inc.'s 466% move, Esperion Therapeutics Inc. with a 416% move, and Nektar Therapeutics with a 354% move.



from Biotech News